Plus Therapeutics Regains Nasdaq Minimum Bid Price Compliance

Key Points for Investors

• Plus Therapeutics, Inc. (Nasdaq: PSTV) has officially regained compliance with the Nasdaq Stock Market’s minimum bid price requirement.
• The company received formal notification from Nasdaq confirming that the issue is now closed.
• This development follows a period where the company was at risk of delisting due to its common stock trading below the \$1.00 threshold.
• For 10 consecutive business days, from April 6, 2026 to April 17, 2026, the company’s closing bid price was at or above \$1.00 per share, meeting Nasdaq Listing Rule 5550(a)(2).
• Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for hard-to-treat central nervous system (CNS) cancers, including leptomeningeal metastases (LM) and recurrent glioblastoma (GBM).

What Shareholders Need to Know

This announcement is highly significant and potentially price-sensitive for shareholders:

• Regaining compliance with Nasdaq’s minimum bid price requirement removes the immediate risk of delisting from the exchange, which could have had significant negative consequences for share liquidity, institutional ownership, and investor confidence.
• Nasdaq’s formal closure of the compliance matter should reassure the market and could support the share price moving forward.
• Maintaining the listing is crucial for future capital raising activities and for keeping Plus Therapeutics visible to both existing and prospective investors.
• The company’s pipeline targets difficult CNS cancers, an area of high unmet need, and it has established strategic partnerships to support product development and potential commercialization.

Company Background and Strategic Progress

Headquartered in Houston, Texas, Plus Therapeutics is advancing a pipeline of innovative radiopharmaceutical product candidates. The company focuses on a combination of image-guided local beta radiation and targeted drug delivery approaches. Its lead programs are in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM), both of which represent significant treatment challenges and market opportunities.

Plus Therapeutics has also established a supply chain through strategic partnerships, which positions it well for future development, manufacturing, and potential commercialization of its products.

Investor Relations Contact

For further information, investors can contact Plus Therapeutics via their investor relations partner, CORE IR, at [email protected].

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Investors should conduct their own due diligence and consult with their financial advisors before making any investment decisions.

View PLUS THERAPEUTICS, INC. Historical chart here